Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Strong Trading Volume - Here's Why

Key Points

• Trading volume surged 403% to approximately 3.6 million shares, while Fresenius Medical Care’s stock traded near $21.28, below its prior close of $21.94.
• Analyst sentiment remains cautious: seven analysts rate the stock a Hold and four rate it a Sell, resulting in an average “Reduce” rating and a consensus price target of $23.42.
• The company exceeded quarterly expectations, reporting $0.66 EPS versus a $0.62 estimate and $5.55 billion in revenue versus a $5.48 billion consensus forecast; institutional investors own 8.37% of the stock.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) saw strong trading volume on Tuesday. Approximately 3,597,782 shares were traded during mid-day trading, an increase of 403% from the previous session's volume of 715,173 shares. The stock last traded at $21.2810 and had previously closed at $21.94.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Sanford C. Bernstein increased their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a "market perform" rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Citigroup restated a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Truist Financial lowered their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a "hold" rating for the company in a report on Monday, October 12th. Finally, Berenberg Bank set a $24.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 29th. Seven research analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Price Performance

The business has a fifty day moving average of $22.60 and a 200 day moving average of $22.88. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. The stock has a market cap of $11.50 billion, a PE ratio of 11.09, a P/E/G ratio of 4.10 and a beta of 0.74.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. The company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. Sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 39.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company's stock valued at $43,000 after acquiring an additional 538 shares in the last quarter. Advisors Preferred LLC lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 6.1% in the first quarter. Advisors Preferred LLC now owns 10,226 shares of the company's stock worth $231,000 after purchasing an additional 589 shares in the last quarter. Allworth Financial LP lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the second quarter. Allworth Financial LP now owns 3,552 shares of the company's stock worth $80,000 after purchasing an additional 850 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% during the first quarter. Parallel Advisors LLC now owns 4,632 shares of the company's stock worth $104,000 after purchasing an additional 1,011 shares during the period. Finally, Mather Group LLC. boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% during the third quarter. Mather Group LLC. now owns 1,407 shares of the company's stock worth $31,000 after purchasing an additional 1,257 shares during the period. Institutional investors own 8.37% of the company's stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.